Everolimus in Patients (pts) with Advanced Lung Carcinoids: Evaluation of Median Progression Free Survival (PFS) and Median Time to First Dose Decrease or Discontinuation (DDD)

#1225

Introduction: Treatment of well-differentiated (WD) lung neuroendocrine tumors (NETs) is challenging. Everolimus (mTOR inhibitor) has shown encouraging results in digestive NETs but data about its activity on lung carcinoid are sparse.

Aim(s): The aim of our study was to assess antitumoral efficacy and tolerability of everolimus in lung NETs.

Materials and methods: Consecutive pts with progressive advanced WD lung NETs treated with everolimus at Gustave Roussy between Sep 2007 and Feb 2014 were analyzed. Treatment regimen with oral everolimus was 10 mg daily. Primary end-points were median PFS and median time to first DDD. Secondary objective were overall survival (OS), best response (RECIST v1.1) and safety.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Gianoncelli L, Guigay J, Caramella C, Borget I, Mir O,

Keywords: lung carcinoid, everolimus, mTOR inhibitor,